EMA Reflection Paper on risk based Quality Management in Clinical Trials

On the Road to 30,000 Members

Let us become the World's Leading GMP/GDP Compliance Community in 2026

Let us become the World's Leading GMP/GDP Compliance Community in 2026

The European Medicines Agency EMA has recently released a draft reflection paper on risk based quality management in clinical trials.

The purpose of this reflection paper is to facilitate the development of a more systematic, prioritised, risk-based approach to quality management of clinical trials, to support the principles of Good Clinical Practice and to complement existing quality practices, requirements and standards.

Please also see the reflection paper available for consultation for further details.

Comments related to this reflection paper should be provided using this template. The completed comments form should be sent to GCP@ema.europa.eu.

Please note that the deadline for comments for this reflection paper is 15 February 2012.

Related GMP News

03.06.2026In-use Storage Time of Reconstituted Medicines

28.05.2026New EMA Q&A on the Implementation of 3DP Technology

28.05.2026EMA publishes Presentations on Contractual Agreements in Clinical Trials

28.05.2026UK Substantial Modifications Pilot

07.05.2026What are the GMP Requirements for Investigational Medicinal Products (IMPs)?

07.05.2026CTIS - Update of Important Sponsor Documents

Go back

NEWSLETTER

Stay informed with the GMP Newsletters from ECA

GMP Newsletter

The ECA offers various free of charge GMP newsletters for which you can subscribe to according to your needs.

To subscribe, please click here.